Avandia, and the Vioxx ghost

The news that the Food and Drug Administration may have ignored warning signs that Avandia, Glaxo Smith Kline's diabetes drug, could significantly increase the chance...

The news that the Food and Drug Administration may have ignored warning signs that Avandia, Glaxo Smith Kline's diabetes drug, could significantly increase the chance of a heart attack was the latest public relations nightmare for an already embattled agency.

An editorial in the New York Times mentions Vioxx in the first paragraph (no, it will never go away), and legislators are already attacking the FDA. How this will play out in the long run is still anything but certain, but it wouldn't be surprising if concerned players began jockeying for position as an FDA re-think begins to feel less an outside possibility and more an inevitability.

As for GSK, Eleanor Trickett recently weighed in on the challenge information excess is providing for pharma PR pros. Much more to come on Avandia as the probe continues.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in